Skip to main content
IP

Imagine Pharma

Imagine Pharma develops a novel polypeptide platform that enables oral delivery of biologic drugs, eliminating the need for injections and improving patient compliance. Their focus on therapeutic and regenerative medicine aims to address conditions such as diabetes and enhance wound healing through first-in-class treatments.

Founded 2016181K+ followers
Updated 20 months ago

Funding

$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

II
Funding rounds are not available yet.

Founders

Product

Problem

Many biologic drugs require administration via injection, which can lead to poor patient compliance, pain, and inconvenience. This limits the potential of these therapies, especially for chronic conditions requiring frequent dosing.

Solution

Imagine Pharma is developing a novel polypeptide platform (IMG-1) designed to enable oral delivery of biologic drugs, eliminating the need for injections. This platform has applications across three areas: oral delivery of biologics, novel therapeutics, and regenerative medicine. The oral delivery platform allows injectable biologic drugs to be administered orally. The therapeutics platform focuses on developing novel treatments across multiple disease states, either disrupting current treatments or providing treatments where none exist. The regenerative medicine platform uses a proprietary culture to promote the propagation and production of several critical body cell types.

Target Audience

The primary target audience includes patients with chronic conditions requiring biologic drugs, healthcare providers seeking to improve patient compliance, and researchers in therapeutic and regenerative medicine.

Features

  • Novel polypeptide (IMG-1) platform for oral delivery of biologics
  • Therapeutics platform developing treatments for multiple disease states
  • Regenerative medicine platform promoting the production of critical body cell types
  • First-in-class innovative therapies and treatments
  • Human islet isolation services for autologous clinical transplantation
This profile is AI-generated and may contain inaccuracies.